Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023

Upgrades

Ladenburg Thalmann upgraded the previous rating for Edison International EIX from Sell to Neutral. Edison Intl earned $1.01 in the second quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $74.92 and a 52-week-low of $54.51. At the end of the last trading period, Edison Intl closed at $69.76.

For Hannon Armstrong Sustainable Infrastructure Capital Inc HASI, B of A Securities upgraded the previous rating of Neutral to Buy. Hannon Armstrong earned $0.53 in the second quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $44.41 and a 52-week-low of $21.31. Hannon Armstrong closed at $23.12 at the end of the last trading period.

Janney Montgomery Scott upgraded the previous rating for Shore Bancshares Inc SHBI from Neutral to Buy. For the second quarter, Shore Bancshares had an EPS of $0.25, compared to year-ago quarter EPS of $0.39. The current stock performance of Shore Bancshares shows a 52-week-high of $20.49 and a 52-week-low of $10.65. Moreover, at the end of the last trading period, the closing price was at $11.39.

Oppenheimer upgraded the previous rating for Redfin Corp RDFN from Underperform to Perform. Redfin earned $0.25 in the second quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $17.68 and a 52-week-low of $3.08. At the end of the last trading period, Redfin closed at $10.16.

According to Raymond James, the prior rating for CareDx Inc CDNA was changed from Market Perform to Outperform. CareDx earned $0.18 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.54 and a 52-week-low of $6.22. CareDx closed at $9.35 at the end of the last trading period.

According to Morgan Stanley, the prior rating for Pharvaris NV PHVS was changed from Equal-Weight to Overweight. Pharvaris earned $0.69 in the second quarter, compared to $0.40 in the year-ago quarter. The stock has a 52-week-high of $21.71 and a 52-week-low of $1.80. At the end of the last trading period, Pharvaris closed at $18.42.

RBC Capital upgraded the previous rating for Hexcel Corp HXL from Sector Perform to Outperform. In the second quarter, Hexcel showed an EPS of $0.50, compared to $0.33 from the year-ago quarter. The current stock performance of Hexcel shows a 52-week-high of $79.08 and a 52-week-low of $50.25. Moreover, at the end of the last trading period, the closing price was at $69.11.

For NextDecade Corp NEXT, Stifel upgraded the previous rating of Hold to Buy. NextDecade earned $0.23 in the first quarter, compared to $0.14 in the year-ago quarter. The current stock performance of NextDecade shows a 52-week-high of $8.94 and a 52-week-low of $3.92. Moreover, at the end of the last trading period, the closing price was at $5.53.

See all analyst ratings upgrades.

Downgrades

According to Laidlaw & Co., the prior rating for Alaunos Therapeutics Inc TCRT was changed from Buy to Hold. In the second quarter, Alaunos Therapeutics showed an EPS of $0.04, compared to $0.05 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.01 and a 52-week-low of $0.38. Alaunos Therapeutics closed at $0.39 at the end of the last trading period.

According to SVB Leerink, the prior rating for Galecto Inc GLTO was changed from Outperform to Market Perform. Galecto earned $0.41 in the second quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $3.70 and a 52-week-low of $1.06. At the end of the last trading period, Galecto closed at $2.34.

For Chicken Soup for the Soul Entertainment Inc CSSE, Craig-Hallum downgraded the previous rating of Buy to Hold. For the second quarter, Chicken Soup for the Soul had an EPS of $1.50, compared to year-ago quarter EPS of $1.28. The stock has a 52-week-high of $13.44 and a 52-week-low of $0.94. At the end of the last trading period, Chicken Soup for the Soul closed at $1.01.

For Design Therapeutics Inc DSGN, Wedbush downgraded the previous rating of Outperform to Neutral. Design Therapeutics earned $0.36 in the second quarter, compared to $0.27 in the year-ago quarter. The stock has a 52-week-high of $26.30 and a 52-week-low of $4.90. At the end of the last trading period, Design Therapeutics closed at $7.33.

According to Alliance Global Partners, the prior rating for Chicken Soup for the Soul Entertainment Inc CSSE was changed from Buy to Neutral. Chicken Soup for the Soul earned $1.50 in the second quarter, compared to $1.28 in the year-ago quarter. The stock has a 52-week-high of $13.44 and a 52-week-low of $0.94. At the end of the last trading period, Chicken Soup for the Soul closed at $1.01.

Mizuho downgraded the previous rating for BioXcel Therapeutics Inc BTAI from Buy to Neutral. For the second quarter, BioXcel Therapeutics had an EPS of $1.83, compared to year-ago quarter EPS of $1.35. The current stock performance of BioXcel Therapeutics shows a 52-week-high of $34.12 and a 52-week-low of $3.81. Moreover, at the end of the last trading period, the closing price was at $4.33.

According to Citigroup, the prior rating for Gol Intelligent Airlines Inc GOL was changed from Buy to Neutral. In the second quarter, Gol Intelligent Airlines showed an EPS of $0.48, compared to $0.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.59 and a 52-week-low of $2.00. Gol Intelligent Airlines closed at $3.71 at the end of the last trading period.

For Design Therapeutics Inc DSGN, SVB Leerink downgraded the previous rating of Outperform to Market Perform. For the second quarter, Design Therapeutics had an EPS of $0.36, compared to year-ago quarter EPS of $0.27. The current stock performance of Design Therapeutics shows a 52-week-high of $26.30 and a 52-week-low of $4.90. Moreover, at the end of the last trading period, the closing price was at $7.33.

According to B of A Securities, the prior rating for Valero Energy Corp VLO was changed from Buy to Neutral. Valero Energy earned $5.40 in the second quarter, compared to $11.36 in the year-ago quarter. The stock has a 52-week-high of $160.16 and a 52-week-low of $97.76. At the end of the last trading period, Valero Energy closed at $136.50.

For PBF Energy Inc PBF, B of A Securities downgraded the previous rating of Buy to Neutral. For the second quarter, PBF Energy had an EPS of $2.29, compared to year-ago quarter EPS of $10.58. The stock has a 52-week-high of $50.43 and a 52-week-low of $27.02. At the end of the last trading period, PBF Energy closed at $49.52.

According to B of A Securities, the prior rating for Marathon Petroleum Corp MPC was changed from Buy to Neutral. Marathon Petroleum earned $5.32 in the second quarter, compared to $10.61 in the year-ago quarter. The stock has a 52-week-high of $149.76 and a 52-week-low of $89.41. At the end of the last trading period, Marathon Petroleum closed at $148.54.

According to B of A Securities, the prior rating for HF Sinclair Corp DINO was changed from Buy to Neutral. For the second quarter, HF Sinclair had an EPS of $2.60, compared to year-ago quarter EPS of $5.59. The current stock performance of HF Sinclair shows a 52-week-high of $66.17 and a 52-week-low of $37.12. Moreover, at the end of the last trading period, the closing price was at $57.95.

According to RBC Capital, the prior rating for Design Therapeutics Inc DSGN was changed from Outperform to Sector Perform. In the second quarter, Design Therapeutics showed an EPS of $0.36, compared to $0.27 from the year-ago quarter. The current stock performance of Design Therapeutics shows a 52-week-high of $26.30 and a 52-week-low of $4.90. Moreover, at the end of the last trading period, the closing price was at $7.33.

HC Wainwright & Co. downgraded the previous rating for Zynerba Pharmaceuticals Inc ZYNE from Buy to Neutral. For the first quarter, Zynerba Pharmaceuticals had an EPS of $0.21, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $1.38 and a 52-week-low of $0.25. At the end of the last trading period, Zynerba Pharmaceuticals closed at $1.35.

For 22nd Century Group Inc XXII, TD Cowen downgraded the previous rating of Outperform to Market Perform. 22nd Century Group earned $1.40 in the second quarter, compared to $0.95 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.82 and a 52-week-low of $2.10. 22nd Century Group closed at $2.29 at the end of the last trading period.

According to Citigroup, the prior rating for Agiliti Inc AGTI was changed from Buy to Neutral. For the second quarter, Agiliti had an EPS of $0.14, compared to year-ago quarter EPS of $0.19. The current stock performance of Agiliti shows a 52-week-high of $20.11 and a 52-week-low of $10.76. Moreover, at the end of the last trading period, the closing price was at $11.71.

For Forward Air Corp FWRD, Baird downgraded the previous rating of Outperform to Neutral. In the second quarter, Forward Air showed an EPS of $0.91, compared to $2.04 from the year-ago quarter. The current stock performance of Forward Air shows a 52-week-high of $121.38 and a 52-week-low of $72.16. Moreover, at the end of the last trading period, the closing price was at $73.23.

Truist Securities downgraded the previous rating for Avid Technology Inc AVID from Buy to Hold. In the second quarter, Avid Technology showed an EPS of $0.22, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $33.41 and a 52-week-low of $19.78. At the end of the last trading period, Avid Technology closed at $26.60.

For Pennant Park Investment Corp PNNT, Compass Point downgraded the previous rating of Buy to Neutral. For the third quarter, Pennant Park Investment had an EPS of $0.35, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $7.07 and a 52-week-low of $4.70. At the end of the last trading period, Pennant Park Investment closed at $6.82.

See all analyst ratings downgrades.

Initiations

Loop Capital initiated coverage on Savers Value Village Inc SVV with a Buy rating. The price target for Savers Value Village is set to $31.00. In the second quarter, Savers Value Village showed an EPS of $0.22, compared to $0.26 from the year-ago quarter. The current stock performance of Savers Value Village shows a 52-week-high of $26.43 and a 52-week-low of $21.50. Moreover, at the end of the last trading period, the closing price was at $25.70.

With a Buy rating, B of A Securities initiated coverage on Turnstone Biologics Corp TSBX. The price target seems to have been set at $18.00 for Turnstone Biologics. The current stock performance of Turnstone Biologics shows a 52-week-high of $13.20 and a 52-week-low of $10.11. Moreover, at the end of the last trading period, the closing price was at $11.73.

SVB Leerink initiated coverage on Cytokinetics Inc CYTK with an Outperform rating. The price target for Cytokinetics is set to $58.00. For the second quarter, Cytokinetics had an EPS of $1.34, compared to year-ago quarter EPS of $0.23. The current stock performance of Cytokinetics shows a 52-week-high of $55.79 and a 52-week-low of $30.66. Moreover, at the end of the last trading period, the closing price was at $32.10.

Cantor Fitzgerald initiated coverage on Computer Programs and Systems Inc CPSI with an Overweight rating. The price target for CPSI is set to $24.00. For the second quarter, CPSI had an EPS of $0.40, compared to year-ago quarter EPS of $0.59. At the moment, the stock has a 52-week-high of $32.86 and a 52-week-low of $19.99. CPSI closed at $20.10 at the end of the last trading period.

With an Overweight rating, Cantor Fitzgerald initiated coverage on R1 RCM Inc RCM. The price target seems to have been set at $20.00 for R1 RCM. For the second quarter, R1 RCM had an EPS of $0.00, compared to year-ago quarter EPS of $0.07. The current stock performance of R1 RCM shows a 52-week-high of $26.44 and a 52-week-low of $6.71. Moreover, at the end of the last trading period, the closing price was at $16.80.

With an Overweight rating, Piper Sandler initiated coverage on Turnstone Biologics Corp TSBX. The price target seems to have been set at $20.00 for Turnstone Biologics. At the moment, the stock has a 52-week-high of $13.20 and a 52-week-low of $10.11. Turnstone Biologics closed at $11.73 at the end of the last trading period.

With a Buy rating, Roth MKM initiated coverage on New Found Gold Corp NFGC. The price target seems to have been set at $9.00 for New Found Gold. For the first quarter, New Found Gold had an EPS of $0.08, compared to year-ago quarter EPS of $0.14. The current stock performance of New Found Gold shows a 52-week-high of $5.70 and a 52-week-low of $2.93. Moreover, at the end of the last trading period, the closing price was at $4.47.

Barclays initiated coverage on ODDITY Tech Ltd ODD with an Overweight rating. The price target for ODDITY Tech is set to $57.00. In the second quarter, ODDITY Tech showed an EPS of $0.56, compared to $0.33 from the year-ago quarter. The stock has a 52-week-high of $56.00 and a 52-week-low of $45.66. At the end of the last trading period, ODDITY Tech closed at $46.35.

JP Morgan initiated coverage on Frontline Plc FRO with a Neutral rating. The price target for Frontline is set to $20.00. In the first quarter, Frontline showed an EPS of $0.87, compared to $0.02 from the year-ago quarter. The stock has a 52-week-high of $19.29 and a 52-week-low of $10.11. At the end of the last trading period, Frontline closed at $17.66.

JP Morgan initiated coverage on Euronav NV EURN with an Overweight rating. The price target for Euronav is set to $21.50. At the moment, the stock has a 52-week-high of $21.00 and a 52-week-low of $12.94. Euronav closed at $17.63 at the end of the last trading period.

Oppenheimer initiated coverage on Knife River Holding Co KNF with an Outperform rating. The price target for Knife River Holding is set to $65.00. Knife River Holding earned $1.00 in the second quarter, compared to $0.68 in the year-ago quarter. The stock has a 52-week-high of $52.40 and a 52-week-low of $33.67. At the end of the last trading period, Knife River Holding closed at $50.55.

With an Overweight rating, Keybanc initiated coverage on ODDITY Tech Ltd ODD. The price target seems to have been set at $60.00 for ODDITY Tech. ODDITY Tech earned $0.56 in the second quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $56.00 and a 52-week-low of $45.66. ODDITY Tech closed at $46.35 at the end of the last trading period.

See all analyst ratings initiations.